AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 study for breakthrough and acute agony AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical business focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced that it has dosed the first topics in a Phase 2 today, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate.S. Army Medical Study and Materiel Command, or USAMRMC.6 million grant to aid the advancement of ARX-04, a proprietary non-invasive, fast-onset sublingual product candidate for the treating moderate-to-severe acute agony. Now the most recent research finds that serious acne itself escalates the risk for suicidal actions and thoughts, raising more questions about the role of the medication, if any, in suicide.Outcomes Characteristics of the scholarly study Participants Of the 2508 participants originally recruited, 2416 had an HRCT scan available and were one of them analysis. Of the 2416 participants, 1171 were women, 613 were black, 1060 were active smokers, and 1002 met the GOLD requirements for COPD. Of the 2416 HRCT scans evaluated, 194 showed interstitial lung abnormalities, 861 had been indeterminate, and 1361 didn’t display interstitial lung abnormalities . Of the 1421 HRCT scans scored by at least two readers , 899 had concordant scores. Among the 522 scans that the evaluations were not concordant, many involved one indeterminate reading; discrepancies in the interpretation of HRCT scans with regards to the presence or lack of interstitial lung abnormalities had been less common .